Merck is granted rights to Xencor's monoclonal antibody patent

07/3/2013 | Genetic Engineering & Biotechnology News

Merck & Co. secured nonexclusive licensing rights to one of Xencor's engineering patents for a monoclonal antibody. The deal allows Merck to use the patent for an undisclosed product and gives it an option to license the same patent for future products. Xencor is entitled to an upfront payment, yearly maintenance fees and potential milestone payments and sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA